HAL Allergy B.V. is extending its GMP contract manufacturing activities for clinical batch supply of both recombinant and viral products. The Dutch inspectorate granted the permit extension following an inspection of operational activities in June.
 
Harry Flore, chief executive officer of HAL Allergy, said, “The fact that the Dutch authorities extended our GMP permit is a big step forward in our goal of becoming a key biotech service company. Our team of specialists offers clients reliable and effective services. Modern production and laboratory facilities and over 50 years experience in vaccine production will be key asset in partnerships with our customers.”